108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
2B4/CD244 信号在免疫调节中的作用及其在感染、癌症和免疫耐受中的角色
Authors Yan C, Lu P, Jiang Y, Miao S, Zhao L, Xu X
Received 3 May 2025
Accepted for publication 6 September 2025
Published 4 October 2025 Volume 2025:14 Pages 1111—1131
DOI https://doi.org/10.2147/ITT.S538126
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Flavio Salazar-Onfray
Chao Yan,1,2,* Peng Lu,3,* Yuzhu Jiang,1,* Shu Miao,4,5 Lichun Zhao,6 Xiaoyan Xu1
1Department of Immunology, Binzhou Medical University, Yantai, Shandong, 264003, People’s Republic of China; 2Institute for Immunology, Chinese Institutes for Medical Research, Beijing, 100069, People’s Republic of China; 3School of Life Sciences, Ludong University, Yantai, Shandong, 264025, People’s Republic of China; 4R&D Department, Hainan Cell Medical Technology Co., Ltd, Haikou, Hainan, 570100, People’s Republic of China; 5R&D Department, Shandong Antaien Biotechnology Co, Ltd, Yantai, Shandong, 264003, People’s Republic of China; 6College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lichun Zhao, Email hyzlc@126.com Xiaoyan Xu, Email xuxiaoyanhappy@163.com
Abstract: 2B4 (CD244), the fourth member of the signaling lymphocyte activation molecule (SLAM) family, is expressed by virtually all human and murine hematopoietic lineages and functions as a context-dependent activating or inhibitory receptor. This review provides a comprehensive update on the gene organization, molecular architecture, glycosylation patterns, and alternatively spliced isoforms of 2B4, highlighting how these structural variables dictate ligand (CD48) affinity and downstream signaling outcome. The roles of 2B4 in natural killer (NK) cells, CD8+ T cells, dendritic cells, myeloid-derived suppressor cells, B cells, eosinophils, and basophils were then systematically demonstrated, emphasizing their dual capacity to either potentiate cytotoxicity and cytokine production or enforce immune tolerance and exhaustion. Mechanistically, the balance between SLAM-associated protein (SAP)-mediated activation and SHP-1/2/SHIP-driven inhibition emerges as a central rheostat that is dynamically tuned by SAP availability, and the microenvironment. Clinically, exaggerated 2B4 signaling is associated with viral persistence in MCMV, HCV, HIV, and SARS-CoV-2 infections, promotes tumor immune escape in melanoma, multiple myeloma, and head-and-neck cancer, and compromises maternal–fetal tolerance, whereas insufficient signaling weakens antimicrobial immunity. Parallel pre-clinical studies validate 2B4 blockade as a rational combinatorial strategy to reinvigorate exhausted CD8+ T and NK cells, while soluble CD48 emerges as a dynamic biomarker of disease activity. Collectively, these insights redefine 2B4 as a systems-level integrator of immune homeostasis and a tractable precision-immunotherapy node whose therapeutic manipulation can rebalance immunity across infection, cancer, and pregnancy.
Keywords: 2B4, immune activation, immune tolerance, infectious disease, neoplastic disease
1Department of Immunology, Binzhou Medical University, Yantai, Shandong, 264003, People’s Republic of China; 2Institute for Immunology, Chinese Institutes for Medical Research, Beijing, 100069, People’s Republic of China; 3School of Life Sciences, Ludong University, Yantai, Shandong, 264025, People’s Republic of China; 4R&D Department, Hainan Cell Medical Technology Co., Ltd, Haikou, Hainan, 570100, People’s Republic of China; 5R&D Department, Shandong Antaien Biotechnology Co, Ltd, Yantai, Shandong, 264003, People’s Republic of China; 6College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang, 550025, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lichun Zhao, Email hyzlc@126.com Xiaoyan Xu, Email xuxiaoyanhappy@163.com
Abstract: 2B4 (CD244), the fourth member of the signaling lymphocyte activation molecule (SLAM) family, is expressed by virtually all human and murine hematopoietic lineages and functions as a context-dependent activating or inhibitory receptor. This review provides a comprehensive update on the gene organization, molecular architecture, glycosylation patterns, and alternatively spliced isoforms of 2B4, highlighting how these structural variables dictate ligand (CD48) affinity and downstream signaling outcome. The roles of 2B4 in natural killer (NK) cells, CD8+ T cells, dendritic cells, myeloid-derived suppressor cells, B cells, eosinophils, and basophils were then systematically demonstrated, emphasizing their dual capacity to either potentiate cytotoxicity and cytokine production or enforce immune tolerance and exhaustion. Mechanistically, the balance between SLAM-associated protein (SAP)-mediated activation and SHP-1/2/SHIP-driven inhibition emerges as a central rheostat that is dynamically tuned by SAP availability, and the microenvironment. Clinically, exaggerated 2B4 signaling is associated with viral persistence in MCMV, HCV, HIV, and SARS-CoV-2 infections, promotes tumor immune escape in melanoma, multiple myeloma, and head-and-neck cancer, and compromises maternal–fetal tolerance, whereas insufficient signaling weakens antimicrobial immunity. Parallel pre-clinical studies validate 2B4 blockade as a rational combinatorial strategy to reinvigorate exhausted CD8+ T and NK cells, while soluble CD48 emerges as a dynamic biomarker of disease activity. Collectively, these insights redefine 2B4 as a systems-level integrator of immune homeostasis and a tractable precision-immunotherapy node whose therapeutic manipulation can rebalance immunity across infection, cancer, and pregnancy.
Keywords: 2B4, immune activation, immune tolerance, infectious disease, neoplastic disease